Search Results
Mar 31, 2026, 09:07 ET Dominari 2025 Revenue Surges 487% in 2025, Balance Sheet Strengthens Significantly
the principal invested. You can check the background of Dominari Securities LLC and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Mar 30, 2026, 09:53 ET Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
activation and cell elimination. By incorporating dual anti-BCMA binding sites for optimal cell targeting and monovalent-optimized CD3 activity to minimize CRS, HBM7020 demonstrated potent cytotoxicity with broad applications in both immunological and oncology diseases. In August 2023, HBM7020 obtained IND clearance
More news about: Harbour BioMed
Mar 26, 2026, 09:54 ET Keymed Biosciences Announces 2025 Annual Results and Business Updates
multiple myeloma (RRMM). As of July 2025, in the Phase II dose-expansion stage, only 4.7% of subjects experienced Grade 2 cytokine release syndrome (CRS) events, with no immune effector cell-associated neurotoxicity syndrome (ICANS) events occurring. The objective response rate (ORR) in the target dose
More news about: Keymed
Mar 20, 2026, 05:06 ET Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune diseases, solid tumors and hematological
More news about: Antengene Corporation Limited
Mar 19, 2026, 09:44 ET CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
rightDr. Gabriella Bottari, Rome/ItalyThe new kid on the block – Cytokine Release Syndrome (CRS) after CAR-T cell therapyDr. Peter Pickkers, Nijmegen/The NetherlandsIn addition, multiple abstracts and poster
More news about: Cytosorbents Corp
Mar 18, 2026, 07:01 ET Kali Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial of KT501 for Rheumatoid Arthritis
traditional B-cell therapies, KT501 is designed to maximize B-cell killing potency while significantly reducing the risk of cytokine release syndrome (CRS), a common hurdle for T-cell engaging therapies."We are deeply grateful to the patients, lead Principal Investigator Prof. Stephen Hall, and the
More news about: Kali Therapeutics
Mar 18, 2026, 06:20 ET Bengaluru-based TerraTern Emerges As a Global Hub for AI-Powered Immigration, Work & Study Abroad Guidance
programs. For Canada, they optimise Express Entry CRS scores and Provincial Nominee Programs.
More news about: TerraTern
Mar 17, 2026, 20:30 ET Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs
for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies,
More news about: Antengene Corporation Limited
Mar 17, 2026, 05:00 ET Korean Air deploys IBS Software's iFlight Platform to transform Flight Operations and Crew Management
management. Across the hospitality sector, IBS Software offers a cloud-native, unified platform for hotels and travel sellers, including central reservation (CRS), property management (PMS), revenue management (RMS), call centre, booking engine, loyalty, and distribution. For the tour & cruise industry, IBS
More news about: IBS Software
Mar 16, 2026, 08:00 ET Dominari Releases Letter to Shareholders and Clients
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Mar 16, 2026, 08:00 ET Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
July 2025, the FDA approved an additional indication for the intravenous (IV) formulation of AVTOZMA for the treatment of cytokine release syndrome (CRS) in adult and pediatric patients aged two years and older.INDICATION AVTOZMA® (tocilizumab-anoh) IV is an interleukin-6
More news about: Celltrion
Mar 10, 2026, 08:31 ET Ledgible and Label Partner to Streamline Digital Asset Tax Information CARF & DAC8 Reporting and Compliance
Label is a leading provider of automated end-to-end compliance software and expert tax services, specializing in FATCA, CRS, and CARF due diligence and reporting solutions. With a team combining regulatory expertise from top financial institutions and advanced engineering
More news about: Ledgible
Mar 05, 2026, 17:31 ET Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight
epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:Prevalent Cases of CRSDiagnosed Prevalent Cases of CRSDiagnosed Prevalent Cases of CRSwNPGender-specific Diagnosed Prevalent Cases of CRSwNPTotal Treated Cases
More news about: DelveInsight Business Research, LLP
Mar 05, 2026, 15:55 ET Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
SYNDROMECytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TECVAYLI. Initiate treatment with TECVAYLI step-up dosing schedule to reduce risk of CRS. Withhold TECVAYLI until CRS resolves or permanently discontinue based on severity.Neurologic
More news about: Johnson & Johnson
Mar 04, 2026, 09:15 ET Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
fever, and transient liver enzyme elevations; Grade 3 cytopenias were consistent with expected lymphodepletion. CAR-T related cytokine release syndrome (CRS) occurred in 43% of patients (all Grade 1/2), and immune effector cell‑associated neurotoxicity syndrome (ICANS) occurred in 21% (primarily low grade)."In
More news about: Citius Oncology, Inc.
Mar 03, 2026, 17:00 ET Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
technology and proprietary CD3 sequence, a strategy designed to enable effective B cell depletion and reduce the risk of cytokine release syndrome (CRS). This collaboration further underscores AnTenGager™ platform's unique capability in developing next generation novel TCEs with broad applicability
More news about: Antengene Corporation Limited
Mar 03, 2026, 17:00 ET Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases
technology and proprietary CD3 sequence, a strategy designed to enable effective B cell depletion and reduce the risk of cytokine release syndrome (CRS). This collaboration further underscores AnTenGager™ platform's unique capability in developing next generation novel TCEs with broad applicability
More news about: Antengene Corporation Limited
Mar 03, 2026, 01:00 ET Aven Hospitality Announces MCP Enablement Across Its Platform, Strengthening Hotels' Position in AI-Driven Discovery
SynXis Central Reservation System (CRS) and
More news about: Aven Hospitality
Mar 02, 2026, 12:08 ET The Inner Circle acknowledges Wynne Achatz as a Pinnacle Professional Member Inner Circle of Excellence
assisted living options. Her dedication to client service is supported by an impressive set of professional designations, including SFR, RAM, SRES, GRI, CRS, ABR, and C2EX, underscoring her commitment to professional development and industry expertise.Wynne's achievements have been recognized through
More news about: The Inner Circle
Mar 02, 2026, 07:30 ET WhiteHorse Finance, Inc. Announces Fourth Quarter and Full Year 2025 Earnings Results and Declares Quarterly Distribution of $0.25 Per Share and Supplemental Distribution of $0.01 Per Share
Twin Ridge CRS, LP (d/b/a CRS OneSource)(8)
More news about: WhiteHorse Finance, Inc.
Mar 01, 2026, 19:30 ET XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies,
More news about: Antengene Corporation Limited
Feb 27, 2026, 11:05 ET ISS National Lab-Sponsored Payloads Return on SpaceX CRS-33
With the successful return of SpaceX's 33rd Commercial Resupply Services (CRS) mission for NASA, researchers will begin postflight analysis, aiming to advance scientific knowledge that accelerates future R&D in LEO and beyond.
More news about: International Space Station National Lab
Feb 27, 2026, 11:00 ET Choice Hotels International Kicks Off 11th Mastery Tech Summit, Bringing Hands-On AI Experimentation to the Center of Innovation
offer immediate in-app gift card downloads.In 2018, Choice launched choiceEDGE, the industry's first cloud-based central reservation system (CRS).In 2019, Choice became the first hotel company to commit to being 100% on AWS (Amazon Web Services) Cloud.In 2021, Choice launched
More news about: Choice Hotels International, Inc.
Feb 25, 2026, 10:00 ET Centerra's 'Avenue South' Progresses as 140-Acre District Debuts New Identity
any particular security, strategy, or investment. Securities offered through North Capital Private Securities, Member FINRA/SIPC. Its Form CRS may be found
More news about: Realberry
Feb 25, 2026, 08:47 ET RobosizeME Raises $2M Seed Round Led by SeedTwo Capital to Bring AI Workflow Automation to the Global Hotel Industry
hospitality ecosystem."Founded by hospitality veteran and co-founder of Sciant, Stephen Burke, RobosizeME integrates directly with PMS, CRS, POS, and financial systems, deploying AI as a managed service. Workflow automation runs 24/7, handling tasks like OTA commission reconciliation, payment
More news about: SeedTwo Capital Inc.